Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;60(1):117-124.
doi: 10.1002/jcph.1501. Epub 2019 Jul 31.

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval

Kenji Harada  1 , Kazuki Toriyabe  1 , Shunsuke Ono  1
Affiliations

Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval

Kenji Harada et al. J Clin Pharmacol. 2020 Jan.

Abstract

The basic components of regulatory and supporting policies for orphan drug development appear similar between the United States and Japan, but drugs designated as orphan drugs have been different between the 2 countries. The probabilities of development success (ie, marketing approval) in designated orphan drugs have also been significantly different. In this study, we analyzed recent outcomes of development for orphan drugs designated from 1993 to 2017 in Japan, considering their development and approval status in the United States. Our analysis showed that success for orphan drug development in Japan was apparently associated with prior approval status in the United States. Company size, orphan development experience, and patient enrichment were also positively associated with successful marketing approval. Although similar designations and priority review systems for orphan drugs have been enacted, economic incentives and regulatory conditions provided by the systems seem to be different between the 2 countries, which may lead to varied performance in orphan designation and approval. We need to pay close attention to the impact of industrial global development strategies when comparing the outcomes and performance of different orphan drug promotion systems.

Keywords: global development; orphan drug; patient enrichment; probability of success.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart for sample selection. NIBIOHN, National Institutes of Biomedical Innovation, Health, and Nutrition.
See this image and copyright information in PMC

References

    1. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4):267‐268. - PubMed
    1. Dear JW, Lilitkarntakul P, Webb DJ. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol. 2006;62(3):264‐271. - PMC - PubMed
    1. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371(9629):2039‐2041. - PubMed
    1. Electronic Code of Federal Regulations PART 316—Orphan Drugs. https://www.ecfr.gov/cgi-bin/text-idx?SID=7f77960f61d80d3fdca8f02993f23e.... Accessed April 21, 2019.
    1. European Medicines Agency. Orphan designation https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation. Accessed April 21, 2019.

Publication types

MeSH terms